XOMA (XOMA)
(Real Time Quote from BATS)
$25.66 USD
+0.15 (0.59%)
Updated May 20, 2024 11:53 AM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XOMA 25.66 +0.15(0.59%)
Will XOMA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XOMA
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Other News for XOMA
Brookline upgrades Dare Bioscience to Buy on improved funding
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
Buy Rating Affirmed for Xoma with Enhanced Price Target Reflecting New Royalty Assets and Growth Prospects
XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024